Healthcare News | BioTuesdays by Kilmer Lucas IR

Developments

NeuroSense reports positive biomarker study in Alzheimer’s

NeuroSense Therapeutics (NASDAQ:NRSN) reported positive results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense’s combination drug for the treatment of Alzheimer’s disease...

June 30, 2022

Markets

HCW cuts Aileron Therapeutics PT to $1 from $2

H.C. Wainwright reduced its price target for Aileron Therapeutics (NASDAQ:ALRN) to $1 from $2, but maintained its “buy” rating, after the company reported “underwhelming” interim data from a Phase 1 study in non-small...

June 30, 2022

Markets

HCW starts Theseus Pharma at buy; PT $22

H.C. Wainwright launched coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and price target of $22. The stock closed at $5.20 on June 29. “We believe pan-inhibition could be the key to success in...

June 30, 2022

Markets

Cantor assumes coverage of Neximmune at OW; PT $4

Cantor Fitzgerald analyst Prakhar Agrawal assumed coverage of Neximmune (NASDAQ:NEXI) with an “overweight” rating and price target of $4. The stock closed at $1.61 on June 29. Neximmune is developing a novel T-cell...

June 30, 2022

Markets

HCW starts Acumen Pharma at buy; PT $15

H.C. Wainwright initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $15 price target. The stock closed at $4.88 on June 29. Acumen is a clinical-stage biopharmaceutical company developing...

June 30, 2022

Developments

Domain Therapeutics receives multimillion-dollar milestone from Merck

Domain Therapeutics, which operates in France and Canada, obtained a single-digit multimillion-dollar milestone payment from Merck as part of a €240 million collaboration and license partnership signed in 2017. Drug...

June 30, 2022

Markets

WB cuts Aileron Therapeutics to market perform

William Blair downgraded Aileron Therapeutics (NASDAQ:ALRN) to “market perform” after the company released interim data from a Phase trial of ALRN-6924 as a chemoprotectant in patients with non-small cell lung cancer...

June 29, 2022

Developments

Palisade Bio initiates Phase 3 study for postoperative return of bowel function

Palisade Bio (NASDAQ:PALI) initiated a Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. The first clinical site in the U.S. is now open...

June 29, 2022

Executive Moves

Zymeworks names Paul Moore as CSO

Zymeworks (NYSE:ZYME) is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as chief scientific officer, reporting directly to the CEO, effective July 18. Dr. Moore brings more than 25...

June 28, 2022

Executive Moves

Hepion adds accomplished biopharmaceutical executives Anand Reddi and Dr. Kaouthar Lbiati to board

Anand Reddi, M.S. Hepion Pharmaceuticals (NASDAQ:HEPA) appointed Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its board of directors, effective immediately. “Mr. Reddi and Dr. Lbiati have a remarkable wealth...

June 28, 2022

Developments

ENDRA receives 28th U.S. patent for TAEUS system

The United States Patent and Trademark Office has issued a new ENDRA Life Sciences (NASDAQ:NDRA) patent to protect its TAEUS’ radiofrequency (RF) applicator for optimizing the delivery of RF energy to tissue. The...

June 28, 2022

This Week's Feature

Pharvaris providing patient choice in developing oral treatments for hereditary angioedema

Pharvaris (NASDAQ:PHVS), a trans-Atlantic company, is developing two oral products to treat and prevent attacks in all subtypes of hereditary angioedema (HAE), with on-demand and prophylactic therapies.

June 28, 2022

NeuroSense reports positive biomarker study in Alzheimer’s

HCW cuts Aileron Therapeutics PT to $1 from $2

HCW starts Theseus Pharma at buy; PT $22

Cantor assumes coverage of Neximmune at OW; PT $4

HCW starts Acumen Pharma at buy; PT $15

Domain Therapeutics receives multimillion-dollar milestone from Merck

WB cuts Aileron Therapeutics to market perform

Palisade Bio initiates Phase 3 study for postoperative return of bowel function

Zymeworks names Paul Moore as CSO

Hepion adds accomplished biopharmaceutical executives Anand Reddi and Dr. Kaouthar Lbiati to board

ENDRA receives 28th U.S. patent for TAEUS system

Pharvaris providing patient choice in developing oral treatments for hereditary angioedema

General

More